Your browser doesn't support javascript.
loading
Identification of environmental and genetic factors that influence warfarin time in therapeutic range.
Botton, Mariana R; Viola, Patrícia P; Meireles, Mariana R; Bruxel, Estela M; Zuchinali, Priccila; Bandinelli, Eliane; Rohde, Luis E; Leiria, Tiago L L; Salamoni, Joyce Y Y; Garbin, Arthur P; Hutz, Mara H.
Afiliación
  • Botton MR; Universidade Federal do Rio Grande do Sul, Departamento de Genética, Porto Alegre, RS, Brazil.
  • Viola PP; Universidade Federal do Rio Grande do Sul, Departamento de Genética, Porto Alegre, RS, Brazil.
  • Meireles MR; Universidade Federal do Rio Grande do Sul, Departamento de Genética, Porto Alegre, RS, Brazil.
  • Bruxel EM; Universidade Federal do Rio Grande do Sul, Departamento de Genética, Porto Alegre, RS, Brazil.
  • Zuchinali P; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Bandinelli E; Universidade Federal do Rio Grande do Sul, Departamento de Genética, Porto Alegre, RS, Brazil.
  • Rohde LE; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Leiria TLL; Fundação Universitária de Cardiologia, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • Salamoni JYY; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Garbin AP; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Hutz MH; Universidade Federal do Rio Grande do Sul, Departamento de Genética, Porto Alegre, RS, Brazil.
Genet Mol Biol ; 43(1 suppl 2): e20190025, 2020.
Article en En | MEDLINE | ID: mdl-32052826
ABSTRACT
Warfarin is an oral anticoagulant prescribed to prevent and treat thromboembolic disorders. It has a narrow therapeutic window and must have its effect controlled. Prothrombin test, expressed in INR value, is used for dose management. Time in therapeutic range (TTR) is an important outcome of quality control of anticoagulation therapy and is influenced by several factors. The aim of this study was to identify genetic, demographic, and clinical factors that can potentially influence TTR. In total,422 patients using warfarin were investigated. Glibenclamide co-medication and presence of CYP2C9*2 and/or *3 alleles were associated with higher TTR, while amiodarone, acetaminophen and verapamil co-medication were associated with lower TTR. Our data suggest that TTR is influenced by co-medication and genetic factors. Thus, individuals in use of glibenclamide may need a more careful monitoring and genetic testing (CYP2C9*2 and/or *3 alleles) may improve the anticoagulation management. In addition, in order to reach and maintain the INR in the target for a longer period, it is better to discuss dose adjustment in office instead of by telephone assessment. Other studies are needed to confirm these results and to find more variables that could contribute to this important parameter.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Genet Mol Biol Año: 2020 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Genet Mol Biol Año: 2020 Tipo del documento: Article País de afiliación: Brasil